Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 to 75~* BMI ≥ 25.0 kg/m2 \< 36.0 kg/m2~* HbA1c ≥ 7.5% and ≤ 10.5%~* Type 2 Diabetes Mellitus and on stable dose of Metformin. Patients must have been on a stable dose of oral metformin (at least 1000 mg/day) for a minimum of 3 months prior to screening evaluation and will be required to continue their stable dose of metformin throughout the study. Patients on a stable dose of metformin plus a sulfonylurea (SU) or metformin plus a dipeptidyl peptidase-IV (DPPIV) inhibitor for a minimum of 3 months prior to Screening evaluation may be allowed~* Agree to conduct home-based (fasted) blood glucose testing as directed~Exclusion Criteria:~* Clinically significant abnormalities in medical history or physical exam~* Show evidence of uncorrected hypothyroidism or hyperthyroidism~* History of liver transplantation or renal dialysis~* History of liver disease~* History of greater than 3 episodes of severe hypoglycemia within 6 months of screening~* Treatment with any other antidiabetic drug(s) other than metformin, SU or DPPIV within 3 months of screening~* History of diabetic ketoacidosis~* Any other significant illness or condition that may interfere with the patient participating or completing the study~* Inability or unwillingness to comply with protocol or study procedures -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ISIS-GCGRRx (Type: EXPERIMENTAL): ISIS-GCGRRx once weekly dosing for 13 weeks
- Placebo (Type: PLACEBO_COMPARATOR): once weekly dosing for 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).